Literature DB >> 17419990

The two TORCs and Akt.

Prashanth T Bhaskar1, Nissim Hay.   

Abstract

The regulatory circuits that control the activities of the two distinct target of rapamycin (TOR) complexes, TORC1 and TORC2, and of Akt have been a focus of intense research in recent years. It has become increasingly evident that these regulatory circuits control some of the most fundamental aspects of metabolism, cell growth, proliferation, survival, and differentiation at both the cellular and organismal levels. As such, they also play a pivotal role in the genesis of diseases including cancer, diabetes, aging, and degenerative diseases. This review highlights recent developments aimed at deciphering the interplay between Akt and mTORCs as well as their role in embryonic development and in cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17419990     DOI: 10.1016/j.devcel.2007.03.020

Source DB:  PubMed          Journal:  Dev Cell        ISSN: 1534-5807            Impact factor:   12.270


  380 in total

Review 1.  The "other" mTOR complex: New insights into mTORC2 immunobiology and their implications.

Authors:  Helong Dai; Angus W Thomson
Journal:  Am J Transplant       Date:  2019-03-19       Impact factor: 8.086

2.  RHEB/mTOR hyperactivity causes cortical malformations and epileptic seizures through increased axonal connectivity.

Authors:  Martina Proietti Onori; Linda M C Koene; Carmen B Schäfer; Mark Nellist; Marcel de Brito van Velze; Zhenyu Gao; Ype Elgersma; Geeske M van Woerden
Journal:  PLoS Biol       Date:  2021-05-26       Impact factor: 8.029

3.  Mnk earmarks eIF4E for cancer therapy.

Authors:  Nissim Hay
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

4.  Coordinate control of host centrosome position, organelle distribution, and migratory response by Toxoplasma gondii via host mTORC2.

Authors:  Yubao Wang; Louis M Weiss; Amos Orlofsky
Journal:  J Biol Chem       Date:  2010-03-17       Impact factor: 5.157

5.  Akt-dependent Skp2 mRNA translation is required for exiting contact inhibition, oncogenesis, and adipogenesis.

Authors:  Veronique Nogueira; Deepa Sundararajan; Jennifer M Kwan; Xiao-ding Peng; Neha Sarvepalli; Nahum Sonenberg; Nissim Hay
Journal:  EMBO J       Date:  2012-02-03       Impact factor: 11.598

6.  The Rheb-mTOR pathway is upregulated in reactive astrocytes of the injured spinal cord.

Authors:  Simone Codeluppi; Camilla I Svensson; Michael P Hefferan; Fatima Valencia; Morgan D Silldorff; Masakatsu Oshiro; Martin Marsala; Elena B Pasquale
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

7.  Differential requirement of mTOR in postmitotic tissues and tumorigenesis.

Authors:  Caterina Nardella; Arkaitz Carracedo; Andrea Alimonti; Robin M Hobbs; John G Clohessy; Zhenbang Chen; Ainara Egia; Alessandro Fornari; Michelangelo Fiorentino; Massimo Loda; Sara C Kozma; George Thomas; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  Sci Signal       Date:  2009-01-27       Impact factor: 8.192

8.  Protein kinase C-delta and phosphatidylinositol 3-kinase/Akt activate mammalian target of rapamycin to modulate NF-kappaB activation and intercellular adhesion molecule-1 (ICAM-1) expression in endothelial cells.

Authors:  Mohd Minhajuddin; Kaiser M Bijli; Fabeha Fazal; Antonella Sassano; Keiichi I Nakayama; Nissim Hay; Leonidas C Platanias; Arshad Rahman
Journal:  J Biol Chem       Date:  2008-12-13       Impact factor: 5.157

9.  Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cell cytokinesis.

Authors:  Alejandro Vazquez-Martin; Tamara Sauri-Nadal; Octavio J Menendez; Cristina Oliveras-Ferraros; Sílvia Cufí; Bruna Corominas-Faja; Eugeni López-Bonet; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

10.  Computational analysis of an autophagy/translation switch based on mutual inhibition of MTORC1 and ULK1.

Authors:  Paulina Szymańska; Katie R Martin; Jeffrey P MacKeigan; William S Hlavacek; Tomasz Lipniacki
Journal:  PLoS One       Date:  2015-03-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.